HSCT Treatment for patients with Multiple Sclerosis
YEARS
16
3000
PATIENTS
95%
EFFICACY
Citizens of the following countries
are undergoing treatment at the moment
STOP
PROGRESSION OF DISABILITY
Prevent further decrease in the quality of your life
It is a chronic inflammatory disorder of the central nervous system, caused by autoimmune reactivity of T-cells towards components of neural cells.
The disease progresses slowly and, at the end, the patient is essentially confined to a wheelchair.
The disease progresses slowly and, at the end, the patient is essentially confined to a wheelchair.
Leave a constant need for expensive and ineffective therapy.
Modified Therapy helps to limit acute manifestations of the disease, but it cannot stop its progression and in most cases it does not provide a stable long-term effect.
MS progression inevitably leads to impairment of the patient's ability to move, sensitive disturbances and cognitive impairment.
MS progression inevitably leads to impairment of the patient's ability to move, sensitive disturbances and cognitive impairment.
REBOOT
THE DEFECTIVE IMMUNE SYSTEM
ELIMINATE THE CAUSE OF THE DISEASE
ELIMINATE
THE CAUSE OF THE DISEASE
7
STEPS
HOW TO GET RID OF THE DISEASE
2
Takes about 3-4 days
A detailed examination always precedes the final decision.
Link to the stage description A detailed examination always precedes the final decision.
3
About 5-6 days, depending on the results of stem cells collection
Link to the stage description 4
Chemotherapy passes within 4 days, and + 1 more for vacation.
Link to the stage description 5
After finishing chemotherapy
we provide stem cell reinfusion, it takes less than 3 hours
Link to the stage description we provide stem cell reinfusion, it takes less than 3 hours
6
Isolation period during 14 days
to rebuild immune system in the aseptic unit of the hospital.
Link to the stage description to rebuild immune system in the aseptic unit of the hospital.
7
It may take a few months
for your immune system to recover and start a NEW LIFE
Link to the stage description for your immune system to recover and start a NEW LIFE
MEET PEOPLE
DISCOVER THE REAL EXPERIENCE
There are individuals on this forum that have completed the treatment or are currently undergoing treatment, who may be able to answer your questions or provide their insight.
RELEVANT
NEWS AND SERVICES
HSCT for MS: New Updated Results & Approaches 2024, Future Directions 2025+
1. The results of the most effective and safest «R-Flu/Cph» conditioning program (mortality rate 0%, success >80%)
2. New approaches for patients with advanced MS and EDSS>6.5 – Risks and Benefits of HSCT
- How can we help in case of high disability level?
- How to assess prognosis if I make decision to receive HSCT?
- What is my success rate?
- What should I do if HSCT did not help me? (New approaches for patients who failed HSCT)
3. Future directions and development in treatment of autoimmune diseases 2025+
14-17 APRIL 2024
The Annual Meeting of the EBMT is attended by more than 5,500 participants, including physicians, nurses, data managers, statisticians, quality managers, cell therapists, paediatricians, pharmacists, psychologists, psychiatrists and psychoanalysts, transplant coordinators, lab scientists, trainees, patients. This important congress ensures and encourages dialogues and information exchange, education and scientific productivity.
16th of April 2024
Glasgow, United Kingdom
Glasgow, United Kingdom
Program presenter: Denis Fedorenko
16:30 – 17:45
The work is included in the TOP 100 best publications of the congress and opens session.
Clinical Outcomes of High Dose Immunosuppressive Therapy (HDIT) with Autologous Hematopoietic Stem Cell Transplantation in MS patients
Long-Term Single Center Experience
Long-Term Single Center Experience
18:00 – 19:00
Session will take place in Hall 3
Effects Of High Dose Immunosuppressive Therapy with Autologous Hematopoietic Stem Cell Transplantation in MS from patient's perspective:
Long Term Quality Of Life Outcomes
Clinical Outcomes of High Dose Immunosuppressive Therapy (HDIT) with Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in MS patients:
Long-Term Single Center Experience
Long Term Quality Of Life Outcomes
Clinical Outcomes of High Dose Immunosuppressive Therapy (HDIT) with Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in MS patients:
Long-Term Single Center Experience
RESEARCH
Complete our medical questionnaire, describing your previous treatment and current functional status, to define whether HSCT is a meaningful and safe treatment option for you.
Your application will be personally reviewed by MD, PhD, Dr. Denis Fedorenko.
Your application will be personally reviewed by MD, PhD, Dr. Denis Fedorenko.